Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 11Gastrointestinal 5Thoracic 4Sarcoma 2Gynecologic 2Dermatologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Other 1NET 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Classical hematology 1CNS 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 13Fallopian Tube Neoplasms 4Recurrence 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma 2Breast Neoplasms 2Advanced Endometrial Cancer 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Platinum-resistant Recurrent Ovarian Cancer 1Pelvic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasm Metastasis 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Injections × Gynecologic × Clear all
NCT03985072 2022-02-24

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Andes Biotechnologies

Phase 1 Completed
67 enrolled
GastrointestinalGynecologic

Carcinoma, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡